European Commission approves Eylea 8 mg with extended 6-month treatment interval for nAMD and visual impairment due to ...
The European Commission (EC) has granted a label extension in the European Union (EU) for Eylea 8 mg (aflibercept 8 mg, 114.3 mg/ml solution for injection) with extended treatment intervals of up to 6 months for the treatment of two major retinal …